Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CERE-110: Adeno-Associated Virus injection Surgery
CERE-110: Adeno-Associated Virus Surgery · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CERE-110 | EXPERIMENTAL | CERE-110: Adeno-Associated Virus Delivery of NGF |
| Placebo | SHAM_COMPARATOR | Placebo Surgery |
| Name | Type | Description |
|---|---|---|
| CERE-110: Adeno-Associated Virus injection Surgery | DRUG | Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure. |
| Placebo Surgery | PROCEDURE | Placebo Surgery |
Inclusion Criteria: * Diagnosis of mild to moderate Alzheimer's disease * Approved medications for Alzheimer's disease may be taken if the dose has been stable for 3 months * A study partner who can attend all study visits * Good general health * Medically able to undergo neurosurgery Exclusion Cr...
Top 20 of 30 competitors
CERE-110 is an investigational gene therapy developed by Sangamo Therapeutics, Inc. (ticker SGMOQ) for Alzheimer's Disease. It is given as a surgical injection and was studied in a Phase 2 clinical trial. CERE-110 is also known as CERE-110: Adeno-Associated Virus injection Surgery.
CERE-110 was developed for the treatment of mild to moderate Alzheimer's Disease. It is a gene therapy administered through a surgical injection procedure. Its clinical development centered on a single Phase 2 study in subjects with mild to moderate Alzheimer's Disease conducted in the United States.
CERE-110 is developed by Sangamo Therapeutics, Inc., which trades under the ticker SGMOQ. The company sponsored the clinical development of this gene therapy candidate for Alzheimer's Disease.
CERE-110 reached Phase 2 clinical development. It is an investigational gene therapy and is not described as approved. The Phase 2 program has been completed, and there are no active trials of CERE-110.
CERE-110 was studied in one completed Phase 2 trial, NCT00876863, titled a randomized, controlled study evaluating CERE-110 in subjects with mild to moderate Alzheimer's Disease. The trial enrolled 49 participants in the United States, was randomized, double-blind, and sham-controlled, and included participants aged 55 years and older.
Yes, CERE-110: Adeno-Associated Virus injection Surgery is another name for CERE-110. Both refer to the same investigational gene therapy developed by Sangamo Therapeutics, Inc. for Alzheimer's Disease, which was evaluated in the completed Phase 2 trial NCT00876863.